Interferon-alpha (IFN-alpha, IFNA), also known as leukocyte interferon, represents a group of related but distinct proteins that share over 95% amino acid sequence homology. They are members of the type I interferon family which share a common cell surface receptor composed of two subunits, a 100 kDa ligand-binding subunit (IFN-alpha R2) and a 125 kDa ligand binding and signal transduction subunit (IFN-alpha R1) that is involved both in ligand binding and signal transduction. There are at least 18 different IFNA subtypes, and the major subtypes identified are IFNA1, IFNA2, IFNA8, IFNA10, IFNA14 and IFNA21.
Key Product Details
Species Reactivity
Human
Applications
Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 995826
Loading...
Product Specifications
Immunogen
Human embryonic kidney cell line HEK293-derived recombinant human IFN‑ alpha I
Met1-Asp189
Accession # P01571
Met1-Asp189
Accession # P01571
Specificity
Detects human IFN‑ alpha I in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IFN‑ alpha I Antibody
IFN- alpha I Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN- alpha I Antibody.
Recombinant Human IFN- alpha I reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN- alpha I (20 pg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IFN- alpha I Monoclonal Antibody (Catalog # MAB10080). The ND50 is typically 0.6-6 ng/mL.Applications for Human IFN‑ alpha I Antibody
Application
Recommended Usage
Neutralization
Measured by its ability to neutralize IFN‑ alpha I inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The Neutralization Dose (ND50) is typically 0.6-6 ng/mL in the presence of 20 pg/mL Recombinant Human IFN‑ alpha I.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Loading...
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: IFN-alpha I
Long Name
Interferon alpha I
Alternate Names
IFNA17, IFNalpha I
Entrez Gene IDs
3451 (Human)
Gene Symbol
IFNA17
UniProt
Additional IFN-alpha I Products
Product Documents for Human IFN‑ alpha I Antibody
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Human IFN‑ alpha I Antibody
For research use only
Related Research Areas
Customer Reviews for Human IFN‑ alpha I Antibody
There are currently no reviews for this product. Be the first to review Human IFN‑ alpha I Antibody and earn rewards!
Have you used Human IFN‑ alpha I Antibody?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Loading...